During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
A cross-sectional survey of 345 licensed Saudi community pharmacists mapped self-reported medication-adherence strategies, ...
On October 15, 2026, the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council's ...
Six ESMO Trials that Changed Cancer Treatment / cancer, Destiny-Breast03, Durvalumab, enfortumab vedotin pembrolizumab, ESMO, ...
Patient’s Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch) – After 21 Months of Treatment with ...
The DEA wants to criminalize concentrated kratom-derived 7-OH products despite gaps in the evidence supporting its proposed limits.
A new PET imaging approach detected 97.9% of lesions in clear cell renal cell carcinoma (ccRCC), potentially giving ...
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as ...
Cosibelimab (UNLOXCYT; Sun Pharma) received a National Comprehensive Cancer Network (NCCN) Category 2A preferred designation for patients with locally advanced cutaneous squamous cell carcinoma (CSCC) ...
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary ...
Opamtistomig in First-Line EP-NEC (ABSTRACT NO. 5836) As of April 3, 2026, the study had enrolled 69 patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) and no prior systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results